Last reviewed · How we verify

NCT04280939

Spinal Anesthetic for Hip and Knee Replacement Surgery - Intrathecal Morphine or Hydromorphone

Withdrawn NA Last updated 31 March 2022
What this trial tests

NA trial testing spinal anesthesia in Spinal Anesthesia. Withdrawn.

Timeline
1 April 2020
Primary endpoint
31 March 2021
31 March 2021

Quick facts

Lead sponsorHopital Montfort
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Start date1 April 2020
Primary completion31 March 2021
Estimated completion31 March 2021

Drugs / interventions tested

Conditions studied

Sponsor

Hopital Montfort

Who can join

Adults 18 to 95, any sex, with Spinal Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the current healthcare system, a short length of stay is paramount, for medical, functional, and financial reasons. Most patients undergoing hip and knee replacement at Hôpital Montfort institution receive spinal anesthetic, with intrathecal morphine for enhanced analgesia. However, morphine can cause urinary retention, nausea or vomiting resulting in increased length of stay (LOS). Based mainly on local experience, The investigators believe hydromorphone may be a good alternative (1). According to the literature review, no adult study compares morphine and hydromorphone. QUESTIONS Does intrathecal hydromorphone lead to equal or better pain control/post-operative function, with fewer side effects than morphine? OBJECTIVES. Primary objective: to demonstrate that hydromorphone is the choice narcotic for spinal anesthesia for arthroplasty patients. Secondary objectives: * increased patient satisfaction * decreased hospital length of stay METHODOLOGY The investigators propose a prospective randomized double-blind trial with three groups of 155 patients each undergoing total hip arthroplasty (THA), total knee arthroplasty (TKA), or unicompartmental knee arthroplasty (UKA), striving for similar proportions of each procedure in all three groups. * Group 1: spinal anesthetic with standard painkillers, without intrathecal narcotics (ie "placebo" group) * Group 2: spinal anesthetic with intrathecal morphine * Group 3: spinal anesthetic with intrathecal hydromorphone The primary outcome measure will be urinary retention. Secondary outcome measures will be nausea/vomiting, pain control, post-operative function and length of stay. RESULTS The investigators expect to show that intrathecal hydromorphone will provide the best combination of post-operative patient pain control and function, with diminished negative side effects. They hope to extrapolate this to a potential out-patient arthroplasty program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of spinal anesthesia

Trials testing the same drug.

Other recruiting trials for Spinal Anesthesia

Currently open trials in the same condition.

Other Hopital Montfort trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04280939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing